Refine Your Search

  • Solutions

  • Therapeutic Areas

  • Resource Type

Certara Partners with Critical Path Institute to Develop Population-based Lung Model

Computer simulation will be able to mimic drug disposition in the lungs at different stages of tuberculosis infection ST. LOUIS, MISSOURI – September 10, 2013 – Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced that it is partnering with the […]

Solution: PBPK Modeling & Simulation
Therapeutic Area: Infectious Disease
More Info

Simcyp Releases Version 13 of its Widely Used Simulator

New release further expands biologics capabilities and provides new tools for formulation scientists ST. LOUIS, MO – Aug. 28, 2013 – Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced that version 13 of its Simcyp™ Simulator has now been released, […]

Solution: PBPK Modeling & Simulation
More Info

Certara Announces Acquisition of Great Lakes Drug Development, Inc

Acquisition will further increase the depth of Certara’s early drug development analysis, modeling and simulation expertise ST. LOUIS, MO – Aug. 13, 2013 – Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced that it has acquired drug development consultancy firm, […]

More Info

Certara Enhances SYBYL-X Drug Design and Discovery Software Suite

SYBYL-X 2.1 offers improved job control and increased QSAR accessibility ST. LOUIS, MO – Aug. 6, 2013 – Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced the release of version 2.1 of its SYBYL®-X molecular modeling and simulation suite. SYBYL-X […]

More Info

Certara Launches Cardiac Safety Simulator to Help Assess New Drug Candidates’ Arrhythmia Risk

Simulator helps sponsors to assess arrhythmia risk before a candidate enters clinical trials; determine safe drug doses for specific patient populations ST. LOUIS, MO – August 1, 2013 Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced the launch of its Cardiac […]

More Info

Pfizer Deploys Certara’s D360 for Scientific Data Access and Analysis

Bio-IT World News Bulletin describes how Pfizer has adopted D360 as Pfizer’s core research platform.  ST. LOUIS, MO – July 29, 2013 Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced that Pfizer selected Certara’s D360™ software solution for scientific data access […]

Solution: Scientific Informatics
More Info

Certara’s Simcyp Appoints Professor Yuichi Sugiyama to the Certara Scientific Advisory Board

The appointment will help Simcyp maintain and enhance its leadership in the field of predictive pharmacokinetic modelling and simulation. ST. LOUIS, MO – June 5, 2013 Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced that Simcyp Limited, a Certara company and […]

More Info

Certara and Veristat Expand Clinical Trial Service Offerings with New Partnership

Collaboration offers clients more streamlined and efficient approach to clinical trial planning ST. LOUIS, MO and HOLLISTON, MA – May 14, 2013 – Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through clinical development, and Veristat, LLC., a leading full service clinical research organization, today […]

More Info

Time to Tumor Growth Helps Predict Survival Benefit of Bevacizumab for Patients

Paper published in the Journal of Clinical Oncology proposes new mathematical modeling approach to analyzing oncology clinical trial data ST. LOUIS, MO – May 8, 2013 – Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced that its Pharsight Consulting Services has […]

Therapeutic Area: Oncology/Hematology
More Info
Learn More LinkedIn Twitter Facebook Email